Picture of Lytix Biopharma AS logo

LYTIX Lytix Biopharma AS Share Price

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+17.67%
3m-19.9%
6m+2.48%
1yr+25.21%
Volume Change (%)
10d/3m-15.75%
Price vs... (%)
52w High-51.33%
50d MA+9.83%
200d MA-1.16%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-212.98%
Return on Equity-153.1%
Operating Margin-770.25%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Lytix Biopharma AS EPS forecast chart

Profile Summary

Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.

Directors

Last Annual
December 31st, 2023
Last Interim
September 30th, 2024
Incorporated
August 25th, 2003
Public Since
June 14th, 2021
No. of Employees
10
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
no flag iconOslo Stock Exchange
Shares in Issue
49,610,303

LYTIX Share Price Performance

Upcoming Events for LYTIX

Lytix Biopharma AS Annual Shareholders Meeting

Similar to LYTIX

Picture of Arcticzymes Technologies ASA logo

Arcticzymes Technologies ASA

no flag iconOslo Stock Exchange

Picture of Bergenbio ASA logo

Bergenbio ASA

no flag iconOslo Stock Exchange

Picture of Circio Holding ASA logo

Circio Holding ASA

no flag iconOslo Stock Exchange

Picture of Exact Therapeutics AS logo

Exact Therapeutics AS

no flag iconOslo Stock Exchange

Picture of Lifecare ASA logo

Lifecare ASA

no flag iconOslo Stock Exchange

FAQ